SINOPHARM GROUP EBITDA vs. Total Debt
| X2S1 Stock | EUR 13.10 0.20 1.55% |
For SINOPHARM GROUP profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SINOPHARM GROUP to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SINOPHARM GROUP 15ON utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SINOPHARM GROUP's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SINOPHARM GROUP 15ON over time as well as its relative position and ranking within its peers.
SINOPHARM |
SINOPHARM GROUP 15ON Total Debt vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining SINOPHARM GROUP's current stock value. Our valuation model uses many indicators to compare SINOPHARM GROUP value to that of its competitors to determine the firm's financial worth. SINOPHARM GROUP 15ON is rated third in ebitda category among its peers. It is rated second in total debt category among its peers making up about 3.69 of Total Debt per EBITDA. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SINOPHARM GROUP's earnings, one of the primary drivers of an investment's value.SINOPHARM Total Debt vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
SINOPHARM GROUP |
| = | 23.5 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
SINOPHARM GROUP |
| = | 86.79 B |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
SINOPHARM Total Debt vs Competition
SINOPHARM GROUP 15ON is rated second in total debt category among its peers. Total debt of Medical Distribution industry is at this time estimated at about 231.89 Billion. SINOPHARM GROUP totals roughly 86.79 Billion in total debt claiming about 37% of all equities under Medical Distribution industry.
SINOPHARM GROUP Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in SINOPHARM GROUP, profitability is also one of the essential criteria for including it into their portfolios because, without profit, SINOPHARM GROUP will eventually generate negative long term returns. The profitability progress is the general direction of SINOPHARM GROUP's change in net profit over the period of time. It can combine multiple indicators of SINOPHARM GROUP, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GROUP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.
SINOPHARM Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on SINOPHARM GROUP. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SINOPHARM GROUP position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SINOPHARM GROUP's important profitability drivers and their relationship over time.
Use SINOPHARM GROUP in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SINOPHARM GROUP position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SINOPHARM GROUP will appreciate offsetting losses from the drop in the long position's value.SINOPHARM GROUP Pair Trading
SINOPHARM GROUP 15ON Pair Trading Analysis
The ability to find closely correlated positions to SINOPHARM GROUP could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SINOPHARM GROUP when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SINOPHARM GROUP - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SINOPHARM GROUP 15ON to buy it.
The correlation of SINOPHARM GROUP is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SINOPHARM GROUP moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SINOPHARM GROUP 15ON moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SINOPHARM GROUP can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your SINOPHARM GROUP position
In addition to having SINOPHARM GROUP in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cannabis Thematic Idea Now
Cannabis
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in SINOPHARM Stock
To fully project SINOPHARM GROUP's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of SINOPHARM GROUP 15ON at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include SINOPHARM GROUP's income statement, its balance sheet, and the statement of cash flows.